Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse and / or Refractory Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01711671
What this trial is testing

DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Leap Therapeutics, Inc. 8
Testing effectiveness (Phase 2)Looking for participantsNCT07116616
What this trial is testing

MRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc. 190
Testing effectiveness (Phase 2)Study completedNCT04205409
What this trial is testing

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Who this might be right for
Recurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma+15 more
University of Washington 20
Large-scale testing (Phase 3)Study completedNCT02076009
What this trial is testing

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 569
Testing effectiveness (Phase 2)Study completedNCT00619684
What this trial is testing

Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant

Who this might be right for
Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple Myeloma+1 more
Fred Hutchinson Cancer Center 18
Early research (Phase 1)Ended earlyNCT05908396
What this trial is testing

Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
IGM Biosciences, Inc. 4
Large-scale testing (Phase 3)Study completedNCT00657488
What this trial is testing

Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 400
Large-scale testing (Phase 3)Study completedNCT03234972
What this trial is testing

Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 213
Testing effectiveness (Phase 2)Study completedNCT06055075
What this trial is testing

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Hoffmann-La Roche 19
Early research (Phase 1)UnknownNCT04537442
What this trial is testing

Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Beijing Immunochina Medical Science & Technology Co., Ltd. 10
Testing effectiveness (Phase 2)Study completedNCT01394354
What this trial is testing

Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma in Relapse
University Hospital Freiburg 34
Testing effectiveness (Phase 2)Study completedNCT00473590
What this trial is testing

Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)

Who this might be right for
Multiple Myeloma
Genentech, Inc. 102
Testing effectiveness (Phase 2)Looking for participantsNCT06627751
What this trial is testing

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

Who this might be right for
Extramedullary Disease in Multiple MyelomaRecurrent Multiple MyelomaRefractory Multiple Myeloma
Roswell Park Cancer Institute 28
Testing effectiveness (Phase 2)Ended earlyNCT01832727
What this trial is testing

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Amgen 65
Testing effectiveness (Phase 2)UnknownNCT04714827
What this trial is testing

Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Shanxi Province Cancer Hospital 24
Early research (Phase 1)Ended earlyNCT02030483
What this trial is testing

Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma

Who this might be right for
Multiple Myeloma
Weill Medical College of Cornell University 9
Not applicableStudy completedNCT00993694
What this trial is testing

Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+6 more
Vanderbilt University 41
Very early researchActive Not RecruitingNCT05838131
What this trial is testing

Study of CT071 Injection in RRMM or PPCL

Who this might be right for
Multiple MyelomaPrimary Plasma Cell Leukemia
Shanghai Changzheng Hospital 20
Early research (Phase 1)Looking for participantsNCT03017820
What this trial is testing

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Who this might be right for
B-Cell Non-Hodgkin LymphomaHistiocytic and Dendritic Cell NeoplasmMyelodysplastic Syndrome+16 more
Mayo Clinic 99
Large-scale testing (Phase 3)Active Not RecruitingNCT05405166
What this trial is testing

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

Who this might be right for
Plasma Cell Myeloma Recurrent
Sanofi 531
Next Page